emergent logo.jpg
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
March 19, 2019 06:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and...
emergent logo.jpg
CEPI vergibt Vertrag im Wert von bis zu 36 Mio. US-Dollar zur Entwicklung eines Impfstoffs gegen das Lassa-Virus an Profectus BioSciences und Emergent BioSolutions
August 16, 2018 06:15 ET | Emergent Biosolutions, Inc.
OSLO, Norwegen, BALTIMORE und GAITHERSBURG, Maryland, USA, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (die Coalition for Epidemic Preparedness Innovations) gab heute eine neue Kooperation mit Profectus...
emergent logo.jpg
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
August 16, 2018 06:15 ET | Emergent BioSolutions
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus...
Elsevier Publishes Four New Books in Microbiology Portfolio
November 13, 2014 04:00 ET | Elsevier, Inc.
WALTHAM, MA--(Marketwired - November 13, 2014) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of four new...